Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
113.09
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Sep 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
528
Open
113.09
Bid (Size)
113.23 (2)
Ask (Size)
113.48 (4)
Prev. Close
113.09
Today's Range
113.09 - 113.09
52wk Range
99.14 - 134.63
Shares Outstanding
2,531,374,696
Dividend Yield
2.58%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Evaxion Biotech Partners With Merck To Expand Vaccine Development
September 26, 2024
Evaxion Biotech enters an expanded collaboration with Merck, granting an option to license preclinical vaccine candidates. The deal includes $3.2 million upfront and potential earnings up to $592...
Via
Benzinga
Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024
September 26, 2024
From
Merck & Co., Inc.
Via
Business Wire
Performance
YTD
-0.13%
-0.13%
1 Month
-2.93%
-2.93%
3 Month
-12.89%
-12.89%
6 Month
-14.29%
-14.29%
1 Year
+8.80%
+8.80%
More News
Read More
This Is What Whales Are Betting On Merck & Co
September 25, 2024
Via
Benzinga
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
September 25, 2024
Via
Benzinga
Exposures
Product Safety
Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years
September 25, 2024
Via
Benzinga
Exposures
Product Safety
Merck & Co Unusual Options Activity For September 23
September 23, 2024
Via
Benzinga
Exploring NYSE:MRK's dividend characteristics.
September 20, 2024
Via
Chartmill
Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study
September 25, 2024
Via
Benzinga
Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer
September 25, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma
September 25, 2024
From
Merck & Co., Inc.
Via
Business Wire
Behind the Scenes of Merck & Co's Latest Options Trends
September 18, 2024
Via
Benzinga
NYSE:MRK: good value for what you're paying.
September 18, 2024
Via
Chartmill
Competitor Analysis: Evaluating Merck & Co And Competitors In Pharmaceuticals Industry
September 17, 2024
Via
Benzinga
Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus
September 24, 2024
From
Merck & Co., Inc.
Via
Business Wire
Pfizer Advances On Its Cancer Journey
September 20, 2024
Via
Benzinga
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
September 20, 2024
From
Merck & Co., Inc.
Via
Business Wire
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
September 20, 2024
Via
FinancialNewsMedia
Is It Too Late to Buy ServiceNow Stock?
September 20, 2024
Via
The Motley Fool
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
September 20, 2024
From
FN Media Group LLC
Via
GlobeNewswire
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
September 19, 2024
Via
Investor's Business Daily
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
September 18, 2024
Via
Benzinga
Exposures
Product Safety
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.
September 18, 2024
Via
The Motley Fool
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
September 18, 2024
From
Merck & Co., Inc.
Via
Business Wire
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
September 18, 2024
Via
The Motley Fool
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
September 17, 2024
Via
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.